University of California San Francisco

Alan P. Venook, MD

Alan P. Venook - 144
Alan P. Venook, MD

Professor of Clinical Medicine,
Division of Hematology Oncology
Department of Medicine
Chairman, UCSF Committee on Human Research

Address

1450 Third Street, #376
San Francisco, CA 94158
United States

Email: [email protected]
Phone: 415-353-2745
Fax: 415-353-7779

ORCID: 0000-0001-9749-6548

Biography

Dr. Venook is a Medical Oncologist with expertise in Gastrointestinal cancers.  He leads that program in the UCSF 
Helen Diller Family Comprehensive Cancer Center. The program boasts a robust clinical trials portfolio primarily for patients in need of new options.

Education

Institution Degree Dept or School End Date
University of California, San Francisco M.D. Medicine 1980
University of California, San Francisco Residency School of Medicine

Board Certifications

American Board of Internal Medicine
American Board of Internal Medicine: Medical Oncology - Subspecialty
American Board of Internal Medicine: Hematology  - Subspecialty

Awards & Honors

Award Conferred By Date
Giant of Cancer Care in GI Oncology Giants of Cancer Care 2019
Heroes of Hope Award Colon Cancer Alliance 2017
NCCN Board of Producers Award National Comprehensive Cancer Network 2013
Service Excellence Award Healthnetwork Foundation 2011
Director's Service Award National Cancer Institute 2010

Clinical Expertise

Anal Cancer
Colon Cancer
Esophageal Cancer
Hepatocellular Carcinoma (Liver Cancer)
Liver Metastases
Lynch Syndrome
Pancreatic Cancer
Rectal Cancer
Stomach Cancer

Clinical Trials

  1. Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma (NCT01008917)
    Related Conditions: Hepatocellular Cancer, Liver Cancer| Start Date: | End Date:
  2. FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum (NCT00077233)
    Related Conditions: Colorectal Cancer, Colorectal Tumor, Colon Cancer, Rectal Cancer| Start Date: | End Date:

Program Affiliations

UCSF Helen Diller Family Comprehensive Cancer Center
GI Oncology Program
The Liver Center at UCSF

Grants and Funding

  • Cancer Center Support Grant | NIH | 1999-08-05 - 2023-05-31 | Role: Co-Investigator
  • General Clinical Research Center | NIH | 1974-12-01 - 2009-03-31 | Role: Co-Investigator
  • CANCER AND LEUKEMIA GROUP B | NIH | 1993-07-28 - 2003-03-31 | Role: Principal Investigator

Research Interests

Anal Cancer
Colon Cancer
Hepatocellular Carcinoma (Liver Cancer)
Liver Metastases
Rectal Cancer

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 10
  1. How to implement DPYD genotyping into practice.
    Venook AP| | PubMed
  2. BIO26-035: MTAP Deficiency in Thoracic Oncology: Bridging Genomic Loss, Survival Deficits, and Immunosuppressive Microenvironments.
    Walling AM, Sak R, Skootsky S, Wenger N, Balabanova N, Friedberg N, Villalona-Calero M, Schwartz G, Singha S, Bray-Hanin L, Anand S, Jagels B, Dahm L, Cabrera M, Bresnahan A, Meyers B, Sonderlund M, Nelson E, Senthil M, Kane S, Hamdan A, Vu P, Venook A, Burgess D, Gold K| | PubMed
  3. BIO26-035: Validation of an Electronic Health Record Phenotype for Advanced Solid Cancer Across Five University of California Health Systems.
    Walling AM, Sak R, Skootsky S, Wenger N, Balabanova N, Friedberg N, Villalona-Calero M, Schwartz G, Singha S, Bray-Hanin L, Anand S, Jagels B, Dahm L, Cabrera M, Bresnahan A, Meyers B, Sonderlund M, Nelson E, Senthil M, Kane S, Hamdan A, Vu P, Venook A, Burgess D, Gold K| | PubMed
  4. Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database.
    Wagner AD, Raeisi M, Rakez M, Diasio RD, Margalit O, Zalcberg JR, Venook AP, Douillard JY, Lenz HJ, Heinemann V, Goldberg RM, van Cutsem E, Schmoll HJ, Shi Q, André T, de Gramont A| | PubMed
  5. Phase II trial with nivolumab and sorafenib in HCC identified enrichment of immunosuppressive monocytes in patients with Child-Pugh B liver dysfunction.
    Keenan BP, Fan Z, Le BK, Harris Q, Chen J, Clark M, Lea A, Zhang L, Cheung A, Lara F, Gordan JD, Bracci P, Behr SC, Fong L, Venook AP, Kim EJ, Kelley RK| | PubMed
  6. Ending the Controversy Around Pretreatment Dihydropyrimidine Dehydrogenase (DPD/DPYD) Testing Heightens the Controversy Over Appropriate Fluoropyrimidine Dosing.
    Hertz DL, Venook AP| | PubMed
  7. Shifts in the human gut microbiome during cancer chemotherapy are diet-dependent.
    Trepka KR, Van Blarigan EL, Kyaw TS, Olson CA, Partipilo G, Ortega EF, Noecker C, Upadhyay V, Zhang C, Gempis D, Steiding P, Stanfield D, Venook AP, Atreya CE, Kidder WA, Turnbaugh PJ| | PubMed
  8. Clinical and molecular characterization of AXL in colorectal cancer, CALGB (Alliance)/SWOG 80405 and real-world data.
    Ashouri K, Millstein J, Yang Y, Xiu J, Soni S, Mittal P, Algaze S, Torres-Gonzalez L, Jayachandran P, Zhang W, Mumenthaler S, Shields AF, Goldberg R, Lou E, Weinberg BA, Graeber TG, Marshall JL, Venook AP, Hoffmann A, Finley SD, Meyer AS, Battaglin F, Lenz HJ| | PubMed
  9. Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance).
    Dercle L, Geyer S, Nixon AB, Innocenti F, Shi Q, Jacobson SB, Luk L, Liu A, Yang H, Wen Y, Zhao B, Eche T, Mokrane FZ, Yang M, Meyerhardt J, O'Reilly EM, Venook AP, El-Khoueiry AB, Schwartz LH, Abou-Alfa GK| | PubMed
  10. Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study.
    Yamamoto K, Bando H, Misumi T, Nishikawa T, Wakabayashi M, Yamazaki K, Maehara Y, Oki E, Saltz LB, Douillard JY, Punt CJ, Koopman M, Van Cutsem E, Bokemeyer C, Venook AP, Heinemann V, Cremolini C, Randolph Hecht J, Schmoll HJ, Nakayama G, Lenz HJ, Andre T, Shi Q, de Gramont A, Shitara K, Yoshino T| | PubMed